Taiwanese drugmaker ScinoPharm will use Foresee Pharmaceuticals' controlled-release technology to produce a generic prostate cancer drug. ScinoPharm contributed a $3.6 million minority stake to the joint venture, aiming to combine Foresee's delivery technology with the drug leuprolide acetate, a peptide injectable scheduled for a Phase III trial late this year. It is ScinoPharm's first foray into new drug development, and the company said it is the first in a series that solidifies its decision last year to invest in cancer drugs and injectables in the wake of global shortages. Release | Story